N@N

Naked Short Web Site Announces RXII and RVXCF Has Been Removed From Threshold Lists Today

^{Published on 2009-10-20 09:59:21, Last Modified on 2010-12-22 17:10:28 - WOPRAI}
 

October 20, 2009 /M2 PRESSWIRE/ BUYINS.NET, www.buyins.net, announced today that these select companies have been removed from the NASDAQ, AMEX and NYSE naked short threshold lists. RXi Pharmaceuticals (NASDAQ: RXII), ResverLogix (OTC: RVXCF), For a complete list of companies on the naked short lists please visit our web site. To find the SqueezeTrigger Price before a short squeeze starts in any stock, go to http://www.buyins.net .

RXi Pharmaceuticals Corporation (NASDAQ: RXII), a discovery-stage biopharmaceutical company, focuses on the development and commercialization of proprietary therapeutics based on RNA interference for the treatment of human diseases in the United States and internationally. It intends to identify lead compounds and advance towards pre-clinical and clinical development programs in various therapeutic areas, including inflammatory disease; and metabolic diseases, such as obesity and obesity-related type 2 diabetes. The company was formerly known as Argonaut Pharmaceuticals, Inc. and changed its name to RXi Pharmaceuticals Corporation in 2006 before beginning operations in 2007. RXi Pharmaceuticals was founded in 2003 and is based in Worcester, Massachusetts. There is no longer a failure to deliver in shares of RXII.

Resverlogix Corporation (OTC: RVXCF), a biopharmaceutical company, focuses on the development of novel therapeutics in cardiovascular diseases, as well as in related indications in vascular inflammation and Alzheimer's disease. Its development programs include NexVas Plaque Regression, a technology platform, which has completed a Phase Ia safety trial in humans with RVX-208 and progressed to a Phase Ib/IIa clinical trial for the development of drugs that increase ApoA-I to reduce the risk of cardiovascular diseases; NexVas Vascular Inflammation, a discovery stage technology that is in preclinical stages for the development of drugs that target molecular markers of inflammation; NexVas Alzheimer's Disease, a discovery stage technology, which is in Phase I clinical trials for the development of drugs that enhance ApoA-I for the stabilization and regression of Beta Amyloid Plaque; ReVas, a research stage technology for the development of therapeutics to be used with medical devices for the treatment of cardiovascular diseases; and TGF- Shield, a preclinical stage therapeutic for the treatment of grievous proliferative diseases, such as cancer and fibrotic conditions. The company is headquartered in Calgary, Canada. There is no longer a failure to deliver in shares of RVXCF.

About BUYINS.NET

WWW.BUYINS.NET is a service designed to help bonafide shareholders of publicly traded US companies fight naked short selling. Naked short selling is the illegal act of short selling a stock when no affirmative determination has been made to locate shares of the stock to hypothecate in connection with the short sale. Buyins.net has built a proprietary database that uses Threshold list feeds from NASDAQ, AMEX and NYSE to generate detailed and useful information to combat the naked short selling problem. For the first time, actual trade by trade data is available to the public that shows the attempted size, actual size, price and average value of short sales in stocks that have been shorted and naked shorted. This information is valuable in determining the precise point at which short sellers go out-of-the-money and start losing on their short and naked short trades.

BUYINS.NET has built a massive database that collects, analyzes and publishes a proprietary SqueezeTrigger for each stock that has been shorted, www.buyins.com/squeezetrigger.pdf . The SqueezeTrigger database of nearly 2,650,000,000 short sale transactions goes back to January 1, 2005 and calculates the exact price at which the Total Short Interest is short in each stock. This data was never before available prior to January 1, 2005 because the Self Regulatory Organizations (primary exchanges) guarded it aggressively. After the SEC passed Regulation SHO, exchanges were forced to allow data processors like Buyins.net to access the data.

The SqueezeTrigger database collects individual short trade data on over 7,000 NYSE, AMEX and NASDAQ stocks and general short trade data on nearly 8,000 OTCBB and PINKSHEET stocks. Each month the database grows by approximately 50,000,000 short sale transactions and provides investors with the knowledge necessary to time when to buy and sell stocks with outstanding short positions. By tracking the size and price of each montha�s short transactions, BUYINS.NET provides institutions, traders, analysts, journalists and individual investors the exact price point where short sellers start losing money.

All material herein was prepared by BUYINS.NET, based upon information believed to be reliable. The information contained herein is not guaranteed by BUYINS.NET to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. BUYINS.NET is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein. BUYINS.NET may receive compensation in cash or shares from independent third parties or from the companies mentioned.

BUYINS.NET affiliates, officers, directors and employees may also have bought or may buy the shares discussed in this opinion and may profit in the event those shares rise in value. Occasionally companies mentioned in this report pay a $995.00 monthly data fee to Buyins.net for one month of research data. Market commentary provided by Thomas Ronk.

BUYINS.NET will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission.

You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and BUYINS.NET undertakes no obligation to update such statements.

Contact: Thomas Ronk / CEO / www.BUYINS.net / (800) 715-9999 / tom@buyins.net